This webinar will provide an overview of how a pathology laboratory validated a 77-gene next-generation sequencing-based liquid biopsy assay.
Liquid biopsy provides a minimally invasive alternative to tissue biopsy for diagnosis, treatment selection, and monitoring of solid cancers. Liquid biopsy, especially the detection of molecular biomarkers from circulating tumor DNA (ctDNA), has evolved from single biomarker to multi-biomarker measurement with the application of NGS technologies, an advance that promises to improve clinical sensitivity — particularly for the detection of disease relapse and treatment resistance.
To date, the ctDNA-NGS space has been dominated by well resourced commercial providers offering accredited services based on laboratory developed tests. This webinar will describe how the Pathology Department at Australia's Peter MacCallum Cancer Centre is looking to bring this capability in house. Peter Mac's Andrew Fellowes will describe the analytical performance of the Avenio ctDNA Expanded Kit* in a cancer hospital pathology laboratory.
The Avenio ctDNA Expanded Kit* is a commercially available research use only kit based on Cancer Personalized Profiling by Deep Sequencing (CAPP-Seq) that promises to accelerate the uptake of liquid biopsy for clinical research of solid cancers in the clinical laboratory setting.
*For Research Use only, not for use in diagnostic procedures.